Recent progress on rapid SARS-CoV-2/COVID-19 detection by CRISPR-Cas13-based platforms

Drug Discov Today. 2021 Aug;26(8):2025-2035. doi: 10.1016/j.drudis.2021.06.005. Epub 2021 Jun 18.

Abstract

The limitations of conventional diagnostic procedures, such as real-time PCR-based methods and serological tests, have led the scientific community to innovate alternative nucleic acid detection approaches for SARS-CoV-2 RNA, thereby addressing the dire need for increased testing. Such approaches aim to provide rapid, accurate, cost-effective, sensitive, and high-throughput detection of SARS-CoV-2 RNA, on multiple specimen types, and without specialized equipment and expertise. The CRISPR-Cas13 system functions as a sequence-specific RNA-sensing tool that has recently been harnessed to develop simplified and flexible testing formats. This review recapitulates technical advances in the most recent CRISPR-Cas13-based methods for SARS-CoV-2/COVID-19 diagnosis. The challenges and opportunities for implementing mass testing using these novel CRISPR-Cas13 platforms are critically analyzed.

Keywords: CRISPR-Cas13; Collateral cleavage; Point-of-care testing; Rapid detection; SARS-CoV-2/COVID-19; Sherlock.

Publication types

  • Review

MeSH terms

  • COVID-19 Nucleic Acid Testing / methods*
  • COVID-19* / diagnosis
  • COVID-19* / virology
  • CRISPR-Associated Proteins
  • CRISPR-Cas Systems / physiology*
  • Humans
  • Point-of-Care Testing / trends
  • RNA Cleavage
  • RNA, Viral / isolation & purification*
  • SARS-CoV-2 / isolation & purification*

Substances

  • CRISPR-Associated Proteins
  • RNA, Viral